MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme ...

Oncologists and scientists warn that extensive cuts to mRNA funding will have devastating impacts on cancer vaccine ...

AZTR READ THE FULL AZTR RESEARCH REPORT Azitra, Inc. (NYSE:AZTR) reported second quarter 2025 results in an August 11th press ...

Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable ...

Levelle Nutrition Co-founder and CEO Linda Alvarez discusses the timely launch of Cycle Syncing Protein and its broader ...

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...

Recent cuts at the Food and Drug Administration and National Institutes of Health were less like targeted and strategic restructuring and more like a broad stroke to shrink the federal enterprise ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and ...

Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.